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Background: The aim of this study was to investigate whether obestatin (OB), a peptide mediator encoded by the
ghrelin gene exerting a protective effect in ischemic reperfused heart, is able to reduce cardiac dysfunctions in
adult diabetic rats.
Methods: Diabetes was induced by STZ injection (50 mg/kg) in Wistar rats (DM). OB was administered (25 μg/kg)
twice a day for 6 weeks. Non-diabetic (ND) rats and DM rats were distributed into four groups: untreated ND,
OB-treated ND, untreated DM, OB-treated DM. Cardiac contractility and ß-adrenergic response were studied on
isolated papillary muscles. Phosphorylation of AMPK, Akt, ERK1/2 and GSK3ß as well ß-1 adrenoreceptors levels were
detected by western blot, while α-MHC was measured by RT-PCR.
Results: OB preserved papillary muscle contractility (85 vs 27% of ND), ß-adrenergic response (103 vs 65% of ND),
as well ß1-adrenoreceptors and α-MHC levels in diabetic myocardial tissue. Moreover, OB up-regulated the survival
kinases Akt and ERK1/2, and enhanced AMPK and GSK3ß phosphorylation. OB corrected oxidative unbalance,
reduced pro-inflammatory cytokine TNF-α plasma levels, NFkB translocation and pro-fibrogenic factors expression in
diabetic myocardium.
Conclusions: OB displays a significant beneficial effect against the alterations of contractility and ß-adrenergic
response in the heart of STZ-treated diabetic rats, which was mainly associated with the ability of OB to up-regulate
the transcription of ß1-adrenergic receptors and α-MHC; this protective effect was accompanied by the ability to
restore oxidative balance and to promote phosphorylation/modulation of AMPK and pro-survival kinases such as
Akt, ERK1/2 and GSK3ß.
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Cell survival kinasesIntroduction
Obestatin (OB) is a newly discovered peptide encoded
by the ghrelin gene together with acylated (AG) and
unacylated ghrelin (UAG), produced in the oxyntic mu-
cosa of the stomach [1-3]. It has been initially suggested
that OB behaves as a physiological opponent to ghrelin,
through interaction with the orphan G-protein-coupled* Correspondence: manuela.aragno@unito.it
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reproduction in any medium, provided the orreceptor 39 (GPR39) [4]. However, these findings have
been questioned lately and a number of studies have
failed to confirm the anorexigenic effect of obestatin
[5-7] and its agonist properties on GPR39 [8,9]. There-
fore, to date, some biological actions of OB seem to be
controversial and its specific receptor remains unknown.
Recent data suggest a relevant role of peptides encoded
by the ghrelin gene in glucose balance and their implica-
tions for diabetes. Although the direct protective effects
exerted by ghrelin gene-derived peptides on β-cells and
pancreatic islets has been demonstrated in streptozotocin
(STZ)-treated neonatal rats [10-13], to our knowledge,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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myocardial tissue in adult diabetic animals, in which the
ability to induce β-cell regeneration is lost.
OB plays a significant role in cardiac function in
humans, both under physiological and pathological con-
ditions. In particular, higher saliva OB levels were found
in overweight patients with ischemic heart disease com-
pared with healthy controls [14], whereas they are sig-
nificantly decreased in serum of subjects with type 2
diabetes mellitus [1] and obesity [15]. Increased OB
levels and altered ghrelin to OB ratio are present in
chronic heart failure (CHF) patients with cachexia [16],
as well in spontaneously hypertensive rats [17]. OB
improves myocardial function and reduces cell death
and apoptosis of cardiomyocytes after ischemia/reperfu-
sion (I/R) in isolated rat heart [18]. These effects are
probably mediated by OB receptors present on cardiac
cells and by activation of signaling pathways included in
the reperfusion injury salvage kinases (RISK), such as
phosphoinositide 3-kinase (PI3K), protein kinase C
(PKC) and extracellular signal regulated kinases (ERK)
1/2 [18]. In type 1 diabetes, hyperglycemia is the active
element leading to cardiac dysfunctions. Hyperglycemia
promotes the production of reactive oxygen species
(ROS) and contributes to cardiac fibrosis and con-
tractile dysfunctions [19-23]. The protective effects
exerted by OB against myocardial dysfunctions in
ischemic-reperfused heart led us to investigate whether
OB may rescue myocardial contractility and beta adren-
ergic response in the heart of STZ treated diabetic rats.
The main results obtained in this study suggest that OB
displayed a beneficial effect against the reduction of con-
tractility and β-adrenergic response, as well of α-myosin
heavy chain (MHC) and β-1 adrenoreceptors expression
in the heart of STZ-treated diabetic rats, and that
the protective effect is probably related to the ability
of OB to restore oxidative balance and to promote
phosphorylation/modulation of AMPK and pro-survival
kinases such as Akt, ERK1/2 and glycogen synthase
kinase (GSK) 3β.
Materials and methods
Cell culture
H9c2 cardiomyoblasts, an embryonic rat heart-derived
cell line, were obtained from the Istituto Zooprofilattico
Sperimentale della Lombardia e dell’Emilia (Brescia,
Italy) and cultured in 25 cm2 flasks with Dulbecco’s
Modified Eagle Medium (DMEM) containing 10% foetal
calf serum (FCS) at 37°C in a humidified atmosphere
with 95% O2 and 5% CO2. Cells were starved for
24 hours in DMEM with 1% FCS and then treated with
20 mM metformin (Sigma-Aldrich, Milan, Italy), as posi-
tive control for AMPK phosphorylation, or 50 nM OB
(rat obestatin (1–23), produced by conventional solid-phase synthesis and purified (97%) by reverse-phase
HPLC by NeoMPS, Strasbourg, France). H9c2 were then
scraped, centrifugated (1500 rpm, 5 minutes, 4°C) and
lysed for total protein extraction.
Animals
Male Wistar rats (Harlan-Laboratories, Udine, Italy)
weighing 200–220 g were provided with Piccioni pellet
diet (no. 48, Gessate Milanese, Italy) and water ad
libitum. The animals were cared for in compliance
with the Local Ethical Committee and Italian Ministry
of Health Guidelines (no. 86/609/EEC) and with the
Principles of Laboratory Animal Care (NIH no. 85–23,
revised 1985). The scientific project was supervised and
approved by the Italian Ministry of Health, Rome, and
by the ethical committee of the University of Torino.
Animals acute treatment
The effects of an acute treatment with OB or metformin
were tested in a group of fifteen rats. Five rats received a
daily i.p. injection of metformin (250 mg/kg/day) for
three consecutive days, as indicated by Zhou et al. [24].
A second group of five rats received a single dose of OB
by i.p. injection 1 hour before killing, following the same
procedures described by Kola et al. [25] for ghrelin treat-
ment. Five control rats received intraperitoneal injec-
tions of saline. All rats were anesthetized with 90 mg /kg
of Zoletil 100 i.p. (Virbac, Carros, France) and killed by
aortic exsanguinations. Hearts were removed and left
ventricle was excised and rapidly homogenized to obtain
protein extracts for western blotting analyses.
Animals chronic treatment
In a group of rats basal glucose level was measured by
saphenous vein puncture with the Accu-Check Compact
kit (Roche Diagnostics Gmbh, Mannheim, Germany).
Hyperglycemia was induced in a group of rats through a
single injection of streptozotocin (STZ) (50 mg/kg b.wt)
in the tail vein (diabetic, DM). A group of rats received
only the vehicle (non-diabetic, ND). Three days later
glucose was measured and only rats with blood glucose
levels above 200 mg/dL entered the experimental
protocols. ND and DM rats were distributed into four
groups: untreated ND (n = 18) (ND-CTRL), obestatin-
treated ND (n = 10) (ND-OB), untreated DM (n = 20)
(DM-CTRL); obestatin-treated DM (n = 18) (DM-OB).
OB was administered subcutaneously twice a day for
6 weeks, at the final dose of 25 μg/kg/5 ml.
Two days before the sacrifice, after a fasting period of
12 h, a 50% glucose solution at the dose of 3 g/kg was
orally administered to the rats. Glucose levels were
tested 0, 15, 30, 45, 60, 90, 120 and 240 min after glu-
cose loading by saphenous vein puncture.
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anesthetized with Zoletil 100 i.p. and killed by aortic
exsanguinations. Blood was collected and the plasma
isolated and placed at −80°C. Glucose level was immedi-
ately measured. The heart was isolated, weighed and
portions of left ventricle were immediately homogenized
to obtain different tissue extracts. To evaluate papillary
muscles contractility and β-adrenergic response, papil-
lary muscles were isolated from left ventricle, as
described below.Plasma detection
Triglyceride (TG), total cholesterol (TC), high-density-
lipoprotein (HDL) and low density-lipoprotein (LDL)
were determined in plasma by standard enzymatic proce-
dures using reagents kits (Hospitex Diagnostics, Florence,
Italy). Plasma insulin was measured by an ultrasensitive
insulin enzyme-linked immunosorbent assay kit from
DRG Diagnostics (Marburg, Germany). The content of
TNF-α was determined by using a rat TNF-α ELISA kit
(Diaclone, Besancon, France) following the manufacturer’s
guidelines. Each sample was tested in duplicate and aver-
aged. Final results were calculated from the kit standards
and expressed as picograms of TNF-α per milliliter.Protein extraction
For cytosolic and nuclear proteins extraction, left
ventricles were homogenized at 10% (w/v) using a
Potter Elvehjem homogenizer (Wheaton, NJ, USA) in
a homogenization buffer [20 mM HEPES, pH 7.9,
1 mM MgCl2, 0.5 mM EDTA, 1 mM EGTA, 1 mM
dithiothreitol (DTT), 0.5 mM phenylmethylsulphonyl
fluoride (PMSF), 5 μg/ml aprotinin, and 2.5 μg/ml
leupeptin]. Homogenates were cleared by centrifugation
at 1,000 g for 5 min at 4°C. Supernatants were removed
and centrifuged at 15,000 g at 4°C for 40 min to obtain
the cytosolic fraction. The pelleted nuclei were resus-
pended in an extraction buffer [20 mM HEPES, pH 7.9,
1.5 mM MgCl2, 0.2 mM EDTA, 20% (w/v) glycerol,
1 mM EGTA, 1 mM DTT, 0.5 mM PMSF, 5 μg/ml
aprotinin, and 2.5 μg/ml leupeptin]. The suspensions
were incubated on ice for 30 min for high-salt extrac-
tion followed by centrifugation at 15,000 g for 20 min
at 4°C. The resulting supernatants containing nuclear
proteins were carefully removed and stored.
Total extracts were obtained both from 10% (w/v) left
heart ventricle homogenates and cell lysates in RIPA
buffer [0.5% Nonidet P-40, 0.5% sodium deoxycholate,
0.1% SDS, 10 mmol/l EDTA, and protease inhibitors].
After 40 minutes of incubation in ice, samples were
cleared by centrifugation at 15,000 g at 4°C for 40 min.
Supernatants were removed and stored. Protein contentwas determined using the Bradford assay. Protein extracts
were stored at −80°C until use.Oxidative biochemical parameters
The levels of reactive oxygen species (ROS) were
measured on total extracts using the probe 2’,7’-
dichlorofluorescin diacetate (DCFH-DA) and measured
fluorimetrically [26]. Reduced and oxidized glutathione
content was evaluated in cytosolic fractions following
Owens’s method [27]. The difference between total
glutathione and reduced GSH content represents the
GSSG content (expressed as μg/mg prot.); the ratio
between GSSG content and GSH is considered a good
parameter of antioxidant status. Hydroxynonenal (HNE)
concentration was also determined on cytosol fractions.
After extraction, an aliquot of cytosol was injected into
an HPLC (Waters Associated, Milford, MA, USA) Sym-
metry C18 column (5 mm, 3.9x150 mm). The mobile
phase was acetonitrile:bidistilled water (42%, v/v). The
HNE concentration was calculated by comparison with
a standard solution of HNE of known concentration.Western blot
NFkB-p65 was detected on cytosol and on nuclear
extracts; AMPK, pAMPK, Akt, pAkt, ERK1/2, pERK1/2,
pGSK3β, β1-adrenoreceptor and β-actin were detected
on total extracts. Equal amounts of proteins (60 μg)
were separated on 7.5% SDS-polyacrylamide gels,
then blotted on nitrocellulose membranes (Amersham
Biosciences, Braunschweig, Germany). The membranes
were incubated overnight with primary antibodies and
reacted with appropriated peroxidase-labeled secondary
antibodies (Biorad). Immunoreactive proteins were
detected through the chemiluminescence assay (ECL,
Amersham) and subsequent exposure to film.
Specific bands were quantified by densitometry using
an analytic software (Bio-Rad, Multi-Analyst, Munchen,
Germany) and the net intensity of phosphorylated pro-
teins was normalized for the intensity of the correspond-
ing total protein. β-actin was used as internal loading
control for pGSK3β and cytosolic NFkB, while lamin A
was used for nuclear NFkB.Semiquantitative RT-PCR
Total RNA was extracted from left ventricle using
TriPure Isolation Reagent (Roche Diagnostics). Gene
transcripts for α- and β-MHC, β1-adrenoreceptor,
CTGF, TGFβ1 and GADPH were quantified by PCR. All
experiments were performed on at least three inde-
pendent cDNA preparations. PCR products were elec-
trophoresed on 2% agarose gels and amplification
products were stained with GelStar nucleic acid gel
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were photographed and analyzed with Kodak 1D
Image Analysis software. The primer sequences were:
α-MHC forward 5’ AGCCTCTCATCTCGCATCTC 3’;
reverse 5’ GGACCACCCATC TCACTTT 3’, β-MHC
forward 5’ ACCGCTGAGACAGAGAATGG 3’; reverse
5’ GGGTTGGCTTGGATGATTT 3’, β1-adrenoreceptor
forward 5’ GCCGATCTGG TCATGGGA 3’; reverse
5’ GTTGTAGCAGCGGCGCG 3’, CTGF forward 5’
CAAGGACCG CACGTGGTT 3’; reverse 5’ CCCT
AGCTGCCTACCGACTGGAAGACAC 3’, TGFβ1 for-
ward 5’ CTGCTGGCAA TAGCTTC CTA – 3’; reverse
5’ CGAGCCTTAGTTTGGACAGGAT 3’; GAPDH for-
ward 5’ AGATCCACAACGGATACATT 3’; reverse 5’
TCCCTCAAGATTGTCAGCAA 3’.Papillary muscle and contractility determination
Papillary muscles isolated from the left ventricle were
superfused with oxygenated (100% O2) Tyrode solution
containing (in mM): 154 NaCl, 4 KCl, 2 CaCl2,1
MgCl2, 5.5 glucose, 5 N-(2-hydroxyethyl)-piperazineN’-
ethanesufonic acid (HEPES); pH 7.4 adjusted with
NaOH) warmed to 37°C, and driven at constant fre-
quency (120 beats/min). Isometric twitches were evalu-
ated by a 60–2997 Harvard transducer, visualized on a
Tektronix 2211 digital storage oscilloscope and acquired
and recorded in a Power Mac computer, using the
Labview Software (National Instruments Corp., Texas,
USA). To study the responsiveness to β-adrenergic
stimulation, after 20–30 min equilibration, papillaryTable 1 A. Basal values for cardiac contractility in papillary he
rats and in untreated and OB-treated diabetic rats
A
NON-DIABETIC
CTRL (n = 6) OB (n
Tmax (mN/mm
2) 50.3 ± 7.7 42.8 ±
+ dT/dtmax (mN/s) 15265 ± 1759 14043 ±
- dT/dtmax (mN/s) 7297 ± 874 6785 ±
TPT (ms) 133.3 ± 14.2 114.5 ±
Duration (ms) 379.5 ±48.7 353.5 ±
B Isoproterenol (1 μM)
NON-DIABETIC
CTRL (n = 6) OB (n
Tmax% 189.7 ± 27.8 197.3 ±
+ dT/dtmax% 192.7 ± 40.6 205.0 ±
- dT/dtmax% 250.3 ± 28.1 227.6 ±
TPT% 85.0 ± 2.4 86.6 ±
Duration% 83.3 ± 3.4 85.5 ±
B. Effect of Iso (1 μM) on cardiac contractility. Value expressed as % variation respec
among the different groups (diameter: 0.78 ± 0.08, 0.81 ± 0.12, 1.23 ± 0.15 and 1.18
Values are expressed as means ± SD. Statistical significance: ** P < 0.01vs ND-CTRL; *muscles obtained from the different groups of animals
were treated with isoproterenol (Iso, 1 μM). Preliminary
studies showed that 1 μM was the minimal saturating
concentration of Iso.
Statistical analysis
All values were expressed as means ± SD, and were
analyzed by one-way analysis of variance (ANOVA)
followed by Bonferroni’s multiple comparison test or
by Newman-Keuls multiple range test, when appropri-
ate. P < 0.05 was considered statistically significant.
Results
Obestatin restores papillary muscle contractility in
diabetic rats
To test whether OB is able to protect against the altera-
tions of cardiac function induced by diabetic condition,
contractile force developed by electrically-driven papil-
lary muscles was evaluated both in basal conditions and
after stimulation with Iso (1 μM) to compare basal car-
diac contractility and responsiveness to β-adrenergic
stimulation among the different groups of rats (Table 1,
panel A and B). As expected [28], basal contractility
(panel A) was significantly weaker in papillary muscles
from untreated diabetic rats compared with untreated
non-diabetic muscles; this was evident not only for the
maximal developed mechanical tension (Tmax), but also
for the maximum rate of rise (+dT/dtmax) and the
maximum rate of fall of developed mechanical tension
(−dT/dtmax) (in all the cases, p < 0.001), while noart muscles of untreated and OB-treated non-diabetic
DIABETIC
= 5) CTRL (n = 6) OB (n = 5)
8.4 13.4 ± 6.9*** 60.2 ± 20.5†††
1527 5420 ± 847*** 14688 ± 2165†††
645 4056 ± 953*** 6333 ± 1135††
13.6 111.9 ± 31.4 149.6 ± 9.0
20.2 361.7 ± 75.4 407.6 ± 26.2
DIABETIC
= 5) CTRL (n = 6) OB (n = 5)
48.0 123.8 ± 18.0** 183.2 ± 22.7††
39.2 127.3 ± 16.8** 190.0 ± 31.0††
28.4 126.0 ± 14.2*** 187.6 ± 31.1††
5.9 97.8 ± 4.1*** 90.8 ± 3.3††
10.6 95.6 ± 5.8 90.0 ± 6.8
t to control (before Iso). Papillary muscles did not significantly differ in size
± 0.09 mm, respectively).
** P < 0.001 vs ND-CTRL; †† P < 0.01 vs DM-CTRL; ††† P < 0.001 vs DM-CTRL.
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mechanical tension (TPT) and duration of contraction.
Treatment with OB significantly limited the reduction
of contractility observed in untreated diabetic rats
(p < 0.001). However, OB treatment in non-diabetic rats
did not affect per se contractile properties of papillary
muscles. Moreover, papillary muscles from untreated
diabetic rats showed a reduced inotropic response to
β-adrenergic stimulation, which was 55% stronger in
papillary muscles of untreated non-diabetic rats (p < 0.01:
Table 1, panel B). This difference was also evident for
+ dT/dtmax, -dT/dtmax and TPT. Treatment with OB
significantly rescued the responsiveness of papillary
muscles to β-adrenergic stimulation (p < 0.01 for Tmax,
+dT/dtmax, -dT/dtmax and TPT) in diabetic rats, while
did not affect the response to Iso in non-diabetic rat.
OB treatment did not modify heart weight and heart to
body weight ratio in non-diabetic rats, while diabetic
rats showed a marked decrease in heart weight com-
pared to non-diabetics ones (Table 2). OB treatment in
diabetic rats only led to a slight, not significant reduc-
tion in heart to body weight ratio compared to untreated
diabetic animals. Thus, OB-treated non-diabetic rats
showed a decrease (−20%) of body weight compared to
untreated non-diabetic rats. OB treatment of diabetic
rats did not further reduce body weight in comparison
to untreated diabetic rats (about −44% vs CTRL)
(Table 2).Obestatin promotes β1-adrenoreceptors and α-MHC
expression recovery in diabetic myocardial tissue
The reduced response to Iso stimulation observed in
the heart of diabetic rats has been related to a limited
expression of β1-adrenoreceptors [29,30]. While β1-
adrenoreceptors protein expression showed a marked re-
duction in ventricular tissue of diabetic rats, a significantTable 2 Body weight, heart weight, heart/body weight ratio,
untreated and OB-treated non-diabetic rats and in untreated
protocol time (6 weeks)
NON-DIABETIC
CTRL (n = 12) O
BODY WEIGHT (g) 425 ± 14
HEART WEIGHT (g) 0.89 ± 0.06
HEART/BODY WEIGHT (g/mg) 2.63 ± 0.17
GLUCOSE (mg/dL) 104 ± 18
INSULIN (μg/L) 0.42 ± 0.02
TG (mg/dL) 100.95 ± 6.69 10
LDL (mg/dL) 56.78 ± 7.46 5
HDL (mg/dL) 55.99 ± 5.50 5
TC (mg/dL) 92.58 ± 3.29 9
Values are expressed as means ± SD. Statistical significance: * P < 0.05 vs ND-CTRL; *recovery was observed in diabetic rats treated with OB
(p < 0.05 vs diabetic rats, Figure 1, panel A).
The changes reported in diabetic myocardial tissue
include the switch from α to β myosin isoform chains,
the accumulation of fibronectin and of types I and III
collagen matrix [29]. The expression of α and β iso-
forms of the MHC protein in the left ventricle of all
groups obtained by PCR analysis has been reported in
Figure 1, panel B. In untreated diabetic rats we
observed a decrease in α-MHC and an increase in
β-MHC isoform. OB treatment in diabetic rats partially
rescued the α/β MHC ratio with respect to untreated dia-
betic rats. OB treated non-diabetic rats did not showed
any modification of α/β MHC ratio. On the basis of
obtained data, we looked for molecular mechanisms
underlying the protective effects of OB against contract-
ile impairments induced by diabetic state, by studying
OB effects on oxidative stress, inflammatory response, on
specific pro-survival kinases and pro-fibrogenic factors.Obestatin corrects oxidative unbalance in diabetic heart
The levels of ROS as well as HNE, an end-product of
lipid peroxidation, evaluated in cytosolic fraction of left
ventricular tissue, increased significantly in untreated
diabetic rats (Table 3). When OB was given to diabetic
rats, ROS and HNE levels were drastically reduced if
compared to untreated diabetic rats, being carried back
to the values recorded in untreated non-diabetic rats.
Moreover, the significant increase of GSSG/GSH ratio
observed in diabetic rats further confirmed the occur-
rence of oxidative stress. In OB treated diabetic rats, this
ratio was partially decreased towards values recorded in
non-diabetic rats, suggesting a recovery of the GSH con-
tent (Table 3). OB treatment of non-diabetic rats did not
showed per se any significant effects on oxidative para-
meters in comparison with untreated non-diabetic rats.glucose, insulin level and lipid profile in plasma of
and OB-treated diabetic rats, evaluated at the end of the
DIABETIC
B (n = 5) CTRL (n = 14) OB (n = 13)
344 ± 12* 258 ± 26** 233 ± 27**
0.88 ± 0.08 0.57 ± 0.05*** 0.52 ± 0.05***
2.57 ± 0.07 3.20 ± 0.22** 3.09 ± 0.21*
99 ± 11 388 ± 27*** 372 ± 120***
0.49 ± 0.05 0.18 ± 0.04*** 0.17 ± 0.03***
2.26 ± 9.11 356.68 ± 57.03*** 255.09 ± 21.84**†
9.10 ± 9.22 169.19 ± 14.46*** 112.41 ± 11.98**†
4.26 ± 2.69 25.14 ± 3.38*** 40.89 ± 8.67*†
2.91 ± 9.57 123.11 ± 16.68* 104.49 ± 5.41†
* P < 0.01 vs ND-CTRL; *** P < 0.005 vs ND-CTRL; † P < 0.05 vs DM-CTRL.
Figure 1 Representative WB analyses of β1-adrenoreceptor (A) and semiquantitative RT-PCR analyses of α-MHC and β-MHC
(B) expressions in left ventricular tissue RNA extracts from non-diabetic (ND) and diabetic rats (DM), treated or not with OB.
Quantitative analyses are reported in the histograms, which represent the ratio of net intensity of bands with GAPDH. Data are expressed as
percentage variations from the ND-CTRL value. Data are means ± SD of 8–10 rats per group. Statistical significance: * P < 0.05 vs ND-CTRL;
** P < 0.01 vs ND-CTRL; † P < 0.05 DM-CTRL.
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plasma levels and NFkB translocation in the diabetic
myocardium
High levels of cytokines have been found in diabetic
patients and several studies report the stimulatory
effects of high glucose on cytokines production and on
NFkB-dependent signaling activation. OB treatment in
diabetic rats determined a reduction of both the pro-
inflammatory cytokine TNF-α level (Figure 2, panel A)
and the activation of NFkB translocation in the nucleus
(Figure 2, panel B and C).Obestatin up-regulates survival kinases Akt and ERK1/2
in diabetic left ventricular tissue
We observed a significant reduction of Akt and ERK1/2
phosphorylation levels (Figure 3, panel A and B, respect-
ively) in untreated diabetic rats. OB treatment signifi-
cantly enhanced the phosphorylation levels of both these
kinases in non-diabetic rats and rescued their levels in
diabetic rats.Table 3 Oxidative stress parameters evaluated in cardiac tissu
NON-DIABETIC
CTRL (n = 12) OB (n
ROS (U.F./mg prot) 106.67 ± 2.08 106.54
GSSG/GSH (%) 1.60 ± 1.00 1.64
HNE (μM) 0.80 ± 0.08 0.83
Values are expressed as means ± SD. Statistical significance: * P < 0.05 vs ND-CTRL; *
0.01 vs DM-CTRL.Obestatin decreases pro-fibrogenic factors expression
in diabetic heart
In our study, untreated diabetic rats showed a marked
activation of the expression of CTGF and TGF-β, which
represent two important pro-fibrogenic factors, respon-
sible for up-regulated extracellular matrix production.
OB caused a significant reduction in CTGF and TGF-β1
expression respect to that observed in untreated diabetic
rats, as reported in Figure 4. OB treatment in non-
diabetic rats did not exert any modification in compari-
son with untreated non-diabetic rats.Obestatin enhances AMPK and GSK3β phosphorylation
In preliminary experiments to verify whether OB is able
to directly enhance AMPK phosphorylation in H9c2
myocardiocytes (Figure 5, panel A) and in acutely OB
treated rats (Figure 5, panel B), we observed that the
effect of OB was comparable to those induced by met-
formin, a well-known AMPK activator [31]. In accord-
ance with these results, we observed an up-regulation ofe of control, OB, STZ and STZ-treated OB rats
DIABETIC
= 6) CTRL (n = 14) OB (n = 14)
± 15.44 165.67 ± 15.40* 116.43 ± 18.02†
± 0.40 8.91 ± 2.60*** 4.43 ± 3.20†
± 0.08 1.79 ± 0.12** 1.02 ± 0.17††
* P < 0.01 vs ND-CTRL; *** P < 0.005 vs ND-CTRL; † P < 0.05 vs DM-CTRL; †† P <
Figure 2 Representative TNFα plasma concentration determined by ELISA (A). Representative WB analyses of NFkB-p65 in cytosol
(B) and in nucleus (C) obtained from left ventricular tissue from non-diabetic (ND) and diabetic rats (DM), treated or not with OB. Quantitative
analyses are reported in the histograms, which represent the net intensity ratio of bands with α-actin or lamin-B1. Data are expressed
as % variations from the ND-CTRL value. Data are means ± SD of 8–10 rats per group. Statistical significance: * P < 0.05 vs ND-CTRL;
** P < 0.01 vs ND-CTRL; † P < 0.05 vs DM-CTRL.
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addition, OB treatment partially rescued the pAMPK
level in diabetic rats, which showed a marked reduction
of AMPK activity. In addition, the levels of GSK3β, a
substrate of pAkt and pAMPK activity, decreased in
untreated diabetic rats (Figure 5, panel D). OB treatment
in diabetic rats determined a partial recovery of pGSK3β
levels. Taken together, our results suggested that the pro-
tective effect of OB against contractile dysfunction
induced by chronic hyperglycemia is, at least in part, due
to its ability to rescue AMPK and GSK3β phosphorylation.
Obestatin decreases hyperlipemia but not hyperglycemia
in diabetic rats
Glycemia and insulin levels, measured after 6 weeks
from STZ-injection, reflected the hyperglycemic state
caused by the significant reduction of insulin. OB treat-
ment did not determine any modification of glycemia as
well as insulin plasma level in both diabetic and non-diabetic rats (Table 2). In order to find out the effect of
OB on glucose sensitivity, we performed an oral glucose
tolerance test at 6 weeks after STZ injection. Figure 6
shows the effects of oral glucose loading (3 g/kg) in all
groups. In untreated non-diabetic rats and in OB treated
non-diabetic rats, glucose loading transiently increased
plasma glucose levels at time 15 min, with respect to
baseline. In these groups, glycemia returned to normal
values 30 min after glucose loading. The high glucose
level already observed in diabetic rats at time 0, was fur-
ther slightly increased 15 min after glucose loading and
remained significantly higher for up to 240 min. The
time courses describing plasma glucose trajectory in
untreated and OB treated diabetic rats showed a not
significant difference, indicating that OB treatment was
not able to reduce the high glucose levels found in
untreated diabetic rats.
OB given to non-diabetic rats did not modify lipid
profile with respect to untreated non-diabetic rats.
Figure 3 Representative WB analyses of pAkt (A) and pERK1/2 (B) on left ventricle total extracts from non-diabetic (ND) and diabetic
rats (DM), treated or not with OB. Quantitative analyses are reported in the histograms, which represent the net intensity ratio of bands with
total Akt or ERK1/2. Data are expressed as % variations from the ND-CTRL value. Data are means ± SD of 8–10 rats per group. Statistical
significance: * P < 0.05 vs ND-CTRL; ** P < 0.01 vs ND-CTRL; † P < 0.05 vs DM-CTRL; †† P < 0.01 vs DM-CTRL.
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plasma lipid content (triglycerides, LDL, total choles-
terol) vs both untreated non-diabetic rats and OB trea-
ted non-diabetic rats. OB treatment in diabetic rats
partially recovered lipid levels in comparison with
untreated diabetic rats (Table 2). The decrease of HDL
level observed in diabetic rats was partially rescued in
OB treated diabetic rats. Thus, OB treatment, in non-
diabetic and diabetic rats, did not exert any alteration on
glycidic profile, while OB significantly protect against
changes of lipid plasma levels of diabetic rats.
Discussion
The major new findings in this study are that: 1) OB
displayed a beneficial effect against the alterations of con-
tractility and β-adrenergic response in the heart of STZ-
treated diabetic rats; 2) the protective effect is related to
the ability of OB to restore oxidative balance and to pro-
mote phosphorylation/modulation of AMPK and pro-
survival kinases such as Akt, ERK1/2 and GSK3β. To our
knowledge, this is the first report showing that OB is able
to exert a protective action in myocardial tissue affected
by experimentally induced diabetes in adult animals.
OB is a newly discovered peptide, which derives from
the ghrelin peptide precursor pre-pro-ghrelin [1,2,4].
Although it has been suggested that both OB and ghre-
lin participate in a complex regulatory system [32], the
intracellular pathways activated by OB and the role it
plays in physiological and in pathophysiological condi-
tions are largely unknown. Several studies have already
indicated that, in common with ghrelin and other
growth hormone secretagogues, OB protects cardiacmuscle against I/R injury [33]. Moreover, it has been
shown that ghrelin reduces oxidative stress and inhibits
the production of reactive oxygen species [34,35], bio-
logical events that have been implicated in various path-
ologies, including hypertension [36], cardiac ischemia
[37] and myocardial fibrosis [19,20,23,29]. A similar pro-
tective effect has been also reported in primary cardio-
myocytes, as well as in H9c2 cardiomyoblastic cell line
and endothelial cells, in which both ghrelin [21] and
OB [18] inhibit apoptosis induced by doxorubicin or
I/R, by activating ERK1/2, PKC and PI3K/Akt dependent
mechanisms. Several evidences indicate that ghrelin
gene-derived peptides prevent the development of dia-
betes in STZ-treated newborn rats. Indeed, both ghrelin
and OB promote regeneration of β-cells and improve
glucose metabolism in STZ-treated newborn rats, grant-
ing a therapeutic potential in medical conditions asso-
ciated with impaired β-cell function [10-13]. Moreover, a
recent paper showed that ghrelin ameliorated the reduc-
tions in motor and sensory nerve conduction velocities
and reduced oxidative stress in STZ-treated mice [38],
suggesting that ghrelin gene-derived peptides could also
be able to protect against dysfunction in experimentally-
induced diabetes in adult animals, in which it is likely
these peptides have lost their ability to induce β-cell
regeneration. In addition, ghrelin improves both the
metabolic functions and the disturbed energy metabol-
ism in the cardiac muscle of obese diabetic rats [39].
Among all diabetic complications, cardiovascular
disease continues to be the primary cause of morbidity
and mortality. In agreement with other studies [16,40],
we previously reported that diabetic cardiomyopathy
Figure 4 Representative semiquantitative RT-PCR analyses
of CTGF and TGF-β1 in left ventricle RNA extracts from
non-diabetic (ND) and diabetic rats (DM), treated or not with
OB. Quantitative analyses are reported in the histogram, which
represents the ratio of net intensity of bands with GAPDH. Data
are expressed as % variations from the ND-CTRL value. Data are
means ± SD of 8–10 rats per group. Statistical significance:
* P < 0.05 vs ND-CTRL; ** P < 0.01 vs ND-CTRL; † P < 0.05 DM-CTRL.
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myocyte loss and myocardial fibrosis, which lead to
decreased elasticity and impaired contractile function
[29]. Moreover, the enhanced oxidative stress reduced
peak contractile amplitude and maximal velocity of con-
traction and relaxation under basal condition, as well as
the β-adrenergic response in diabetic myocardial tissue
[29,30].
This study demonstrates that OB exerts a protective
effect against the derangement of contractility observed
in papillary muscles from diabetic rats (−65% of mech-
anical tension vs control). The beneficial effect of OB
could be due to its ability to counteract the switch of
cardiac myosin heavy chain gene expression from the
α- to the β-MHC isoform, and the increase of pro-
fibrogenic growth factors, such as TGFβ1 and CTGF,
observed in diabetic myocardial tissue. In addition, OB
was also able to restore the β-adrenergic response by
promoting recovery of β1-adrenoreceptors protein ex-
pression. The molecular mechanisms leading to myocar-
dial dysfunction observed in diabetic myocardial tissueinclude an unbalance between the pro-oxidant and anti-
oxidant compounds and increased inflammatory
process, in terms of TNF-α plasma levels and NFkB ac-
tivation. We observed that OB corrects oxidative unbal-
ance and reduces inflammatory processes in diabetic
myocardium, although, on the basis of our data, we do
not provide a clear evidence that the initial mechanism
upon which OB acts is related to a direct antioxidative
action. We thus investigated the possible molecular
mechanisms and intracellular pathway involved in the
protective effect of OB. OB enhanced AMPK phosphor-
ylation and up-regulated pro-survival kinases Akt,
ERK1/2 and GSK3β in diabetic myocardial tissue. The
ability of OB to enhance pAMPK levels in myocardial
cells was confirmed by in both in vivo and in vitro
models after acute administration of this peptide. Inter-
estingly, the effects of OB were comparable to those
induced by metformin, an anti-diabetic drug known to
stimulate AMPK. AMPK has recently emerged as an
important intracellular signaling pathway in the heart
[31]. In the heart, AMPK is modulated by hormones
such as adiponectin, leptin and ghrelin, or cytokines like
TNFα. A recent paper by Paiva [41], showing that the
administration of metformin during the early reperfu-
sion significantly enhances AMPK phosphorylation,
concomitantly with the reduction of infarct size, high-
lighted the important role of AMPK activation in cardi-
oprotective mechanisms. It has been proposed that
AMPK may protect against reperfusion injury by in-
creasing glucose uptake, if the potential negative conse-
quences of increased fatty acid oxidation are not
present [42]. Since ATP from glycolysis may be prefer-
entially used to support membrane activities such as ion
pumping, a shift in glucose metabolism may play an im-
portant role in cardiac contractile function, metabolic
activity and calcium homeostasis under conditions of
calcium overload, such as post-ischemic recovery [43]
or during β-adrenergic stimulation [44].
In addition, AMPK activation has been involved in
the reduction of inflammatory markers such as TNFα
and NFkB transcription factor [45]. Together with Akt,
AMPK is considered the main signaling molecule con-
trolling cardiac functions [46]. The observed decrease
of cardiac AMPK phosphorylation may therefore con-
tribute, together with reduced Akt signaling, to the
depressed myocardial contractility observed in diabetic
rats. Indeed, it has been recently reported that AMPK
activation may induce an enhancement of L-type cal-
cium current I(Ca) and a prolongation of the action
potential duration in cardiomyocytes [47].
Besides AMPK, OB induced phosphorylation of Akt,
ERK1/2 and GSK3β, pro-survival kinases known to exert
a protective role against oxidative stress [20,23,48], and
proposed as integral components of a protective cascade
Figure 5 Representative WB analyses of pAMPK in H9c2 cells treated with metformin or obestatin (A), in left ventricle of rat subjected
to acute treatment with metformin or OB (B) and in left ventricle of non-diabetic (ND) and diabetic rats (DM), treated or not with OB
for 6 weeks (C). Representative WB analyses of pGSK3β (D) in left ventricle of non-diabetic (ND) and diabetic rats (DM), treated or not with OB
for 6 weeks. Quantitative analyses are reported in the histograms, which represent the net intensity ratio of bands with total AMPK or β-actin.
Data are expressed as percentage variations from the ND-CTRL value. Data are means ± SD of 8–10 rats per group. Statistical significance:
* P < 0.05 vs ND-CTRL; ** P < 0.01 vs ND-CTRL; *** P < 0.005 vs ND-CTRL; † P < 0.05 vs DM-CTRL; †† P < 0.01 vs DM-CTRL.
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[49,50]. The involvement of these kinases in the action
of OB has been already shown in the proliferation of
human retinal pigment epithelial and gastric cancer cells
[51,52], and in rodent β-cells and human pancreatic
islets cell survival [10,11].
Oxidative stress can trigger the opening of the mitochon-
drial membrane permeability transition pore (mPTP) and
lead to a significant loss of mitochondrial NAD+ stores and
subsequent derangement of cellular energy reserves and in-
tact cellular functions. Mitochondrial dysfunction plays an
important role in the development of diabetes and insulin
resistance, and proper cellular function during diabetes
requires the maintenance of mitochondrial membrane
potential [23]. The present study shows that OB also
promoted phosphorylation/inactivation of GSK3β. GSK3βis a substrate of multiple pro-survival protein kinases, in-
cluding Akt and ERK1/2, and is therefore a step to which
multiple protective signaling pathways converge [53]. Since
phosphorylated GSK3β limits the opening of mPTP, it is
reasonable to think that GSK3β inactivation plays a crucial
role in the protective effect afforded by OB in diabetic
myocardial tissue.
We cannot exclude, however, that the protective effect
of OB may result from additional mechanisms not investi-
gated in the present study, such as the nitric oxide (NO)
pathway activation. Recent results, indeed, indicate that
increased NO availability attenuates some alterations in
metabolism and gene expression associated with insulin
resistance induced by a high fat diet [54].
A still open question regards the earliest receptor-
initiated mechanisms involved in the action of OB.
Figure 6 Blood glucose tolerance test in non-diabetic (ND)
and diabetic rats (DM), treated or not with OB. Concentration
time-profile after glucose load given per os as described in Materials
and Methods. Data are mean ± SD for six-ten animals per group.
Statistical significance: *** P < 0.001vs ND-CTRL; ### P < 0.001 vs time 0.
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protein-coupled receptor-39 (GPR39) [4], subsequent
studies were unable to demonstrate binding of OB to
GPR39 or a stimulatory function of the OB peptide on
GPR39-transfected cells [8,9], and the original proposal
that OB acts as a ligand of GPR39 has been retracted [28].
We have recently provided evidence that specific OB
receptors are present in ventricular myocardial cells [18],
with a receptor density and binding affinity quite close to
those previously found in rodent and human pancreatic β-
cells, where OB promotes cell survival and induces expres-
sion of genes involved in the regulation of β-cell mass and
function [10,11]. In conclusion, although to date the pre-
cise role of OB in cardiovascular pathophysiology remains
still partially unknown, the observed beneficial effect in
diabetic myocardial tissue confirms the relevance of this
peptide as a physiological agent exerting protective effects
against cardiac dysfunction and oxidative stress, already
shown in the case of ischemic/reperfused heart.
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